Immunogenicity analysis of conserved fragments in Plasmodium ovale species merozoite surface protein 4.
Avidity index
Conservation
Cross-reactivity
Immunogenicity
MSP4
Plasmodium ovale species
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
30 Mar 2020
30 Mar 2020
Historique:
received:
17
01
2020
accepted:
23
03
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
21
10
2020
Statut:
epublish
Résumé
There is an urgent need for an effective vaccine to control and eradicate malaria, one of the most serious global infectious diseases. Plasmodium merozoite surface protein 4 (MSP4) has been listed as a blood-stage subunit vaccine candidate for malaria. Infection with Plasmodium ovale species including P. ovale wallikeri and P. ovale curtisi, is also a source of malaria burden in tropical regions where it is sometimes mixed with other Plasmodium species. However, little is known about P. ovale MSP4. The msp4 gene was amplified through polymerase chain reaction using genomic DNA extracted from blood samples of 46 patients infected with P. ovale spp. and amplified products were sequenced. Open reading frames predicted as immunogenic peptides consisting of 119 and 97 amino acids of P. ovale curtisi MSP4 (PocMSP4) and P. ovale wallikeri MSP4 (PowMSP4), respectively, were selected for protein expression. Recombinant proteins (rPoMSP4) were expressed in Escherichia coli, purified, analysed, and immunized in BALB/c mice. The specificity of anti-MSP4-immunoglobulin (Ig) G antibodies was evaluated by Western blot and enzyme-linked immunosorbent assays, and cellular immune responses were analysed via lymphocyte proliferation assays. Full peptide sequences of PocMSP4 and PowMSP4 were completely conserved in all clinical isolates, except in the epidermal growth factor-like domain at the carboxyl terminus where only one mutation was observed in one P. o. wallikeri isolate. Further, truncated PoMSP4 segments were successfully expressed and purified as ~ 32 kDa proteins. Importantly, high antibody responses with end-point titres ranging from 1:10,000 to 1:2,560,000 in all immunized mouse groups were observed, with high IgG avidity to PocMSP4 (80.5%) and PowMSP4 (92.3%). Furthermore, rPocMSP4 and rPowMSP4 cross-reacted with anti-PowMSP4-specific or anti-PocMSP4-specific antibodies. Additionally, anti-PoMSP4 IgG antibodies showed broad immuno-specificity in reacting against rPoMSP1 and rPoAMA1. Lastly, PocMSP4- and PowMSP4-immunized mice induced cellular immune responses with PocMSP4 (36%) and PowMSP4 cells (15.8%) during splenocyte proliferation assays. Findings from this study suggest conservation in PoMSP4 protein sequences and high immunogenicity was observed in rPoMSP4. Furthermore, induction of immune responses in PocMSP4- and PowMSP4-immunized mice informed that both humoral and cellular immune responses play crucial roles for PoMSP4 in protection.
Sections du résumé
BACKGROUND
BACKGROUND
There is an urgent need for an effective vaccine to control and eradicate malaria, one of the most serious global infectious diseases. Plasmodium merozoite surface protein 4 (MSP4) has been listed as a blood-stage subunit vaccine candidate for malaria. Infection with Plasmodium ovale species including P. ovale wallikeri and P. ovale curtisi, is also a source of malaria burden in tropical regions where it is sometimes mixed with other Plasmodium species. However, little is known about P. ovale MSP4.
METHODS
METHODS
The msp4 gene was amplified through polymerase chain reaction using genomic DNA extracted from blood samples of 46 patients infected with P. ovale spp. and amplified products were sequenced. Open reading frames predicted as immunogenic peptides consisting of 119 and 97 amino acids of P. ovale curtisi MSP4 (PocMSP4) and P. ovale wallikeri MSP4 (PowMSP4), respectively, were selected for protein expression. Recombinant proteins (rPoMSP4) were expressed in Escherichia coli, purified, analysed, and immunized in BALB/c mice. The specificity of anti-MSP4-immunoglobulin (Ig) G antibodies was evaluated by Western blot and enzyme-linked immunosorbent assays, and cellular immune responses were analysed via lymphocyte proliferation assays.
RESULTS
RESULTS
Full peptide sequences of PocMSP4 and PowMSP4 were completely conserved in all clinical isolates, except in the epidermal growth factor-like domain at the carboxyl terminus where only one mutation was observed in one P. o. wallikeri isolate. Further, truncated PoMSP4 segments were successfully expressed and purified as ~ 32 kDa proteins. Importantly, high antibody responses with end-point titres ranging from 1:10,000 to 1:2,560,000 in all immunized mouse groups were observed, with high IgG avidity to PocMSP4 (80.5%) and PowMSP4 (92.3%). Furthermore, rPocMSP4 and rPowMSP4 cross-reacted with anti-PowMSP4-specific or anti-PocMSP4-specific antibodies. Additionally, anti-PoMSP4 IgG antibodies showed broad immuno-specificity in reacting against rPoMSP1 and rPoAMA1. Lastly, PocMSP4- and PowMSP4-immunized mice induced cellular immune responses with PocMSP4 (36%) and PowMSP4 cells (15.8%) during splenocyte proliferation assays.
CONCLUSION
CONCLUSIONS
Findings from this study suggest conservation in PoMSP4 protein sequences and high immunogenicity was observed in rPoMSP4. Furthermore, induction of immune responses in PocMSP4- and PowMSP4-immunized mice informed that both humoral and cellular immune responses play crucial roles for PoMSP4 in protection.
Identifiants
pubmed: 32228600
doi: 10.1186/s12936-020-03207-7
pii: 10.1186/s12936-020-03207-7
pmc: PMC7106901
doi:
Substances chimiques
Antibodies, Protozoan
0
Antigens, Protozoan
0
Epitopes
0
Immunoglobulin G
0
Protozoan Proteins
0
merozoite surface protein 4, Plasmodium
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
126Références
Pan Afr Med J. 2018 Jun 19;30:142
pubmed: 30374388
Appl Microbiol Biotechnol. 2014 Apr;98(8):3669-78
pubmed: 24146077
PLoS One. 2009 Dec 03;4(12):e8138
pubmed: 19997632
Infect Dis Poverty. 2017 Oct 2;6(1):130
pubmed: 28965490
Infect Immun. 2002 Dec;70(12):6606-13
pubmed: 12438332
J Immunol. 1995 Jul 1;155(1):236-43
pubmed: 7602100
Vaccine. 2017 Dec 4;35(48 Pt B):6720-6726
pubmed: 29042203
Mol Biochem Parasitol. 2005 Jul;142(1):110-5
pubmed: 15878789
J Infect Dis. 2008 Jul 1;198(1):134-42
pubmed: 18471084
Infect Immun. 1997 Nov;65(11):4460-7
pubmed: 9353020
Sci Rep. 2019 Mar 14;9(1):4503
pubmed: 30872745
Malar J. 2019 Jan 18;18(1):11
pubmed: 30658632
Infect Immun. 1999 May;67(5):2193-200
pubmed: 10225874
Malar J. 2019 Sep 18;18(1):317
pubmed: 31533747
Nature. 2017 Feb 2;542(7639):101-104
pubmed: 28117441
Infect Immun. 2000 Oct;68(10):6034-7
pubmed: 10992516
Clin Microbiol Rev. 2005 Jul;18(3):570-81
pubmed: 16020691
Malar J. 2011 Sep 16;10:266
pubmed: 21920045
Malar J. 2017 Feb 10;16(1):67
pubmed: 28183299
Trends Parasitol. 2016 Oct;32(10):808-819
pubmed: 27480365
J Mol Biol. 2007 Mar 9;366(5):1523-37
pubmed: 17229439
Infect Immun. 2006 Jul;74(7):4330-8
pubmed: 16790807
Cold Spring Harb Perspect Med. 2017 Aug 1;7(8):
pubmed: 28389518
BMC Med. 2019 Aug 14;17(1):157
pubmed: 31409398
Infect Immun. 2004 Oct;72(10):5840-9
pubmed: 15385485
Mol Cell Proteomics. 2006 Jul;5(7):1286-99
pubmed: 16603573
N Engl J Med. 2011 Nov 17;365(20):1863-75
pubmed: 22007715
Immunology. 2014 Apr;141(4):628-44
pubmed: 24303947
Curr Opin Allergy Clin Immunol. 2012 Apr;12(2):102-10
pubmed: 22306552
Malar J. 2014 Jun 18;13:240
pubmed: 24946685
Hum Vaccin. 2010 Aug;6(8):627-34
pubmed: 20519960
Front Immunol. 2019 Jun 04;10:1254
pubmed: 31214195
Infect Immun. 2001 Jul;69(7):4390-7
pubmed: 11401978
J Immunol. 2012 May 15;188(10):5041-53
pubmed: 22504652
Parasit Vectors. 2018 Nov 16;11(1):596
pubmed: 30446012
J Infect Dis. 2010 May 15;201(10):1544-50
pubmed: 20380562
Expert Rev Proteomics. 2019 Feb;16(2):117-129
pubmed: 30513025
Mol Biochem Parasitol. 2002 Apr 9;120(2):301-3
pubmed: 11897136
Parasite Immunol. 2006 Jan-Feb;28(1-2):51-60
pubmed: 16438676
Expert Rev Proteomics. 2016 Dec;13(12):1091-1101
pubmed: 27774815
Infect Genet Evol. 2019 Jul;71:224-231
pubmed: 30953716
Int J Parasitol. 2011 May;41(6):677-83
pubmed: 21315074
Malar J. 2016 Sep 07;15:459
pubmed: 27604629
Mol Biochem Parasitol. 2004 Apr;134(2):275-80
pubmed: 15003847